GlassScriptPhysician profile
Tanureet Arora
NPI 1912382201
$1,426.18
in general payments reported to CMS, 2019-2025
31 companies · $405 in 2025
The $405 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.77 · 2022: $321 · 2023: $336 · 2024: $323 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.75 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.51 | 2022-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $127.07 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $119.17 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Lilly USA, LLC | $108.12 | 2022-2024 | Mounjaro, Zepbound |
| Medtronic, INC. | $81.81 | 2022 | |
| Dexcom, INC. | $81.66 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $78.03 | 2022-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $58.84 | 2023-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.29 | 2019-2025 | Ofev, Jardiance |
| Pacira Pharmaceuticals Incorporated | $55.86 | 2024 | Zilretta, Exparel, Iovera |
| Janssen Pharmaceuticals, INC | $52.51 | 2019-2024 | Spravato |
| Averitas Pharma INC. | $42.67 | 2023 | Qutenza |
| Mannkind Corporation | $42.50 | 2025 | |
| Exact Sciences Corporation | $36.17 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $32.36 | 2023-2024 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.78 | 2019-2023 | |
| Arteriocyte Medical Systems, INC. | $29.39 | 2025 | Magellan |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $22.59 | 2025 | |
| Nevro Corp. | $22.18 | 2023 | Senza |
| Beta Bionics, INC. | $21.72 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $18.66 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $18.24 | 2023 | Tirosint, Licart |
| Ionis Pharmaceuticals, INC. | $18.13 | 2025 | Tryngolza |
| Recordati_rare_diseases_inc. | $17.74 | 2025 | Isturisa |
| Dynavax Technologies Corporation | $17.02 | 2025 | Heplisav-B |
| Neurocrine Biosciences, INC. | $16.57 | 2025 | |
| Amarin Pharma, INC. | $14.54 | 2022 | |
| Sanofi Pasteur INC. | $14.31 | 2024 | |
| Sequel Med Tech, LLC | $13.82 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanureet Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.